Advertisement

Journal of Neurology

, Volume 258, Issue 3, pp 464–470 | Cite as

Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients

  • Gulsen Akman-DemirEmail author
  • Erdem Tüzün
  • Patrick Waters
  • Sema İçöz
  • Murat Kürtüncü
  • Sven Jarius
  • Zuhal Yapıcı
  • Melike Mutlu
  • Nilüfer Yeşilot
  • Angela Vincent
  • Mefkure Eraksoy
Original Communication

Abstract

Neuromyelitis optica (NMO) is an inflammatory/demyelinating disorder predominantly affecting the optic nerves and spinal cord. Recent findings showed an underlying humoral abnormality in NMO, characterized by a serum antibody against aquaporin-4 (Aqp-4-Ab). In this study, we evaluated the Aqp-4-Ab status among Turkish patients with NMO to determine the clinical and prognostic relevance. Serum samples from 35 consecutive patients with NMO followed at a single center and diagnosed according to the 2006 revised criteria, were evaluated for Aqp-4-Ab. All samples were obtained during a relapse prior to any immunosuppressive treatment. Aqp-4-Ab was positive in 21/35 (60%) patients. Among these cases, 11 had an EDSS of 6.0 or more, whereas only two patients in the seronegative group had such severe disability (p < 0.05). Overall, seropositive cases had a mean EDSS score of 5.1 ± 2.2 compared with 3.5 ± 1.7 in seronegative cases (p < 0.01). There were trends towards female predominance in seropositive cases and a monophasic course predominance in seronegative cases. Disease duration, age at onset, number of attacks and time to definite NMO did not differ between groups. Our findings in this single-center cohort suggest that the presence of Aqp-4-Ab might have a prognostic significance indicating a more severe disease course.

Keywords

Neuromyelitis optica Multiple sclerosis NMO-IgG Anti aquaporin-4 antibodies Aquaporin-4 seropositivity Prognosis 

References

  1. 1.
    de Seze J, Stojkovic T, Ferriby D, Gauvrit JY, Montagne C, Mounier-Vehier F, Verier A, Pruvo JP, Hache JC, Vermersch P (2002) Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 197:57–61PubMedCrossRefGoogle Scholar
  2. 2.
    Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114PubMedGoogle Scholar
  3. 3.
    Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63:390–396PubMedCrossRefGoogle Scholar
  4. 4.
    Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461PubMedCrossRefGoogle Scholar
  5. 5.
    Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMedCrossRefGoogle Scholar
  6. 6.
    Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477PubMedCrossRefGoogle Scholar
  7. 7.
    Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072–3080PubMedCrossRefGoogle Scholar
  8. 8.
    Akman-Demir G, Eraksoy M, Tüzün E, Jarius S, Icoz S, Kurtuncu M, Waters P, Yapici Z, Mutlu M, Vincent A (2008) Devic’s neuromyelitis optica: an analysis of 47 patients and prognostic implications of NMO IgG status. Neurology 70(Suppl.1):A-267 abstractGoogle Scholar
  9. 9.
    Wingerchuck DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489CrossRefGoogle Scholar
  10. 10.
    Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, Maxwell S, Beeson D, Vincent A (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65:913–919PubMedCrossRefGoogle Scholar
  11. 11.
    Cabrera-Gómez JA, Bonnan M, González-Quevedo A, Saiz-Hinarejos A, Marignier R, Olindo S, Graus F, Smadja D, Merle H, Thomas L, Gómez-García A, Cabre P (2009) Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Mult Scler 15:828–833PubMedCrossRefGoogle Scholar
  12. 12.
    Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133:349–361PubMedCrossRefGoogle Scholar
  13. 13.
    Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566–569PubMedCrossRefGoogle Scholar
  14. 14.
    Kanzaki M, Mochizuki H, Ogawa G, Tanaka K, Araki M, Motoyoshi K, Hammond-Tooke G, Kamakura K (2008) Clinical features of opticospinal multiple sclerosis with anti-aquaporin-4 antibody. Eur Neurol 60:37–42PubMedCrossRefGoogle Scholar
  15. 15.
    Içöz S, Tüzün E, Kürtüncü M, Durmuş H, Mutlu M, Eraksoy M, Akman-Demir G (2010) Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 120:71–75PubMedCrossRefGoogle Scholar
  16. 16.
    Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, Hohlfeld R, Vincent A (2007) NMO IgG in the diagnosis of neuromyelitis optica. Neurology 68:1076–1077PubMedCrossRefGoogle Scholar
  17. 17.
    Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, Watanabe S, Takahashi T, Nishiyama S, Shiga Y, Sato S, Weinshenker BG, Itoyama Y (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 77:1073–1075PubMedCrossRefGoogle Scholar
  18. 18.
    Klawiter EC, Alvarez E 3rd, Xu J, Paciorkowski AR, Zhu L, Parks BJ, Cross AH, Naismith RT (2009) NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 72:1101–1103PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Gulsen Akman-Demir
    • 1
    Email author
  • Erdem Tüzün
    • 1
  • Patrick Waters
    • 2
  • Sema İçöz
    • 1
  • Murat Kürtüncü
    • 3
  • Sven Jarius
    • 2
  • Zuhal Yapıcı
    • 1
  • Melike Mutlu
    • 1
  • Nilüfer Yeşilot
    • 1
  • Angela Vincent
    • 2
  • Mefkure Eraksoy
    • 1
  1. 1.Department of Neurology, Istanbul Faculty of MedicineIstanbul UniversityÇapaTurkey
  2. 2.Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe HospitalUniversity of OxfordOxfordUK
  3. 3.Department of NeurologyAcibadem UniversityIstanbulTurkey

Personalised recommendations